Product Information
TRELEGY ELLIPTA 100-62.5-25 is a brand product labeled by GlaxoSmithKline LLC, priced at $11.0919 per EA under NDC 00173088714. Its NADAC has been published 431 times since May 23, 2018.
FDA first approved this application on Sep 18, 2017.
TRELEGY ELLIPTA 100-62.5-25
fluticasone furoate, umeclidinium bromide and vilanterol trifenatateStrength
100; 62.5; 25 ug/1; ug/1; ug/1
Manufacturer
GlaxoSmithKline LLCNDC
00173088714
Classification
Brand
Dosage Form
POWDER
Route
RESPIRATORY (INHALATION)
Effective Date
8/19/2026
Active Ingredients
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATEApproval Type
New Drug (NDA)
FDA Application
NDA209482FDA Approved
9/18/2017
On Market Since
9/18/2017
Pharmacological Classes
Price Statistics
The NADAC for TRELEGY ELLIPTA 100-62.5-25 has been published 431 times since May 23, 2018, and over the history we have for it it has risen 31.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $11.0919 per EA |
|---|---|
| All-time high | $11.1502 (May 13, 2026) |
| All-time low | $8.4493 (May 23, 2018) |
| 52-week high | $11.1502 |
| 52-week low | $10.7995 |
| Median price | $9.9554 |
| Average price | $9.8512 |
| Largest weekly change | +5.0% (Jan 13, 2021) |
| Weeks tracked | 431 |
| Tracking since | May 23, 2018 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of TRELEGY ELLIPTA 100-62.5-25?
The current National Average Drug Acquisition Cost (NADAC) for TRELEGY ELLIPTA 100-62.5-25, manufactured by GlaxoSmithKline LLC, is $11.0919 per EA (NDC 00173088714), effective Aug 19, 2026.
How has the price of TRELEGY ELLIPTA 100-62.5-25 changed over time?
Over the history we have for it, the NADAC for TRELEGY ELLIPTA 100-62.5-25 has risen 31.3%. It has been tracked across 431 weekly CMS publications since May 23, 2018.
What are the highest and lowest recorded NADAC prices for TRELEGY ELLIPTA 100-62.5-25?
Since May 23, 2018, the NADAC for TRELEGY ELLIPTA 100-62.5-25 has ranged from a low of $8.4493 (May 23, 2018) to a high of $11.1502 (May 13, 2026), with a median of $9.9554 per EA.
Are there cheaper alternatives to TRELEGY ELLIPTA 100-62.5-25?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as TRELEGY ELLIPTA 100-62.5-25 in a comparable dosage form, but none are currently priced below it.
Who manufactures TRELEGY ELLIPTA 100-62.5-25?
TRELEGY ELLIPTA 100-62.5-25 (NDC 00173088714) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.